Background
==========

*Acinetobacter* spp., especially *Acinetobacter baumannii* complex (ABC), has emerged as an important pathogen causing a variety of infections including urinary tract infection, skin and soft tissue infections, and pneumonia and bloodstream infections with high morbidity and mortality \[[@B1]\]. The ability to chronically colonize patients and cause outbreaks which are usually hard to eradicate poses significant challenge to infection control and increases healthcare expenditure \[[@B2]\]. In addition to its intrinsic resistance to many commonly used antibiotics, this troublesome pathogen can gain additional mechanism rapidly in response to new broad-spectrum antibiotics \[[@B3],[@B4]\]. Due to treatment failure, drug-resistant strains have been associated with higher mortality and prolonged hospital stay compared with susceptible ones \[[@B5],[@B6]\].

Carbapenems such as imipenem and meropenem are the last resort of drugs for the treatment of multidrug-resistant pathogens including ABC. However, the incidence of carbapenem resistance in ABC increased steadily in the 2000s \[[@B4],[@B7]\]. In Europe, the MYSTIC program in 2006 revealed a considerable increase in carbapenem resistance rates to 42.5% \[[@B8]\]. Worldwide, the SENTRY program documented an overall increase in imipenem nonsusceptibility from 34.5% in 2006 to 59.8% in 2009 \[[@B9]\]. Imipenem-resistance in Taiwan ranged from 22% in 2000 to 25% in 2005 \[[@B10]\]. Ampicillin/sulbactam, tigecycline, and colistin are possible options for imipenem-resistant ABC but decreasing susceptibility to these agents has also been reported \[[@B1]\]. Surveillance is therefore important in providing useful information for physicians in choosing empirical antibiotics. It also helps to address specific resistant issues within a region to help identify targeted intervention measures \[[@B11],[@B12]\].

Although there have been reports of the high prevalence of drug-resistant ABC in Taiwan \[[@B13],[@B14]\], longitudinal nationwide surveillance data on isolates from different sources in Taiwan have not been published. The Taiwan Surveillance of Antimicrobial Resistance (TSAR) is a nationwide program at the National Health Research Institutes \[[@B11]\] and has been conducted biennially since 1998 \[[@B15]\]. Using data from TSAR, we aimed at detailing the secular change of resistance to various antimicrobial agents in ABC from different sources over 10 years and identify factors associated with imipenem-resistant and extensively drug-resistant ABC (IRABC and XDRABC).

Methods
=======

Study period and isolate collection process
-------------------------------------------

The study period spanned from 2002 to 2010 (corresponding to TSAR period III to VII). Bacterial isolates were collected biennially from July to September by the TSAR program from the same 26 hospitals except TSAR V (2006), in which one hospital did not participate. These hospitals comprised 11 medical centers and 15 regional hospitals, and are located in all 4 regions of Taiwan including 7, 8, 8, and 3 in the north, central, south and east region, respectively. The majority of the Taiwan's population lives in the western part (north, central and south regions) while the eastern part is the least populated region. The collection protocol was similar for all 5 rounds of TSAR as described previously \[[@B16],[@B17]\]. Briefly, each hospital first collected 50 outpatient isolates, 30 adult ICU and 100 non-ICU inpatient isolates, and 20 pediatric isolates. After completion of the above collection, an additional 20 (for TSAR III to V) to 50 (for TSAR VI and VII) isolates from blood and sterile body sites were collected. The isolates were collected sequentially without specifying species. All isolates were stored at −80°C for subsequent testing. The bacterial isolates were recovered from clinical samples taken as part of standard care. The study was approved by the Research Ethics Committee of National Health Research Institutes (EC960205).

Bacterial isolates and information
----------------------------------

For *Acinetobacter* spp., isolates were subcultured to blood agar and McConkey agar plates at our laboratory for purity check and to confirm species identification. Either Vitek I (prior to 2008) or Vitek II (2008 and 2010) GN card was used (bioMérieux, Marcy l\'Etoile, France). In addition, conventional biochemical tests including oxidase, Triple Sugar Iron, 42°C, malonate, and hemolysis on sheep blood agar were used to aid in confirmation of the *A. baumannii* complex \[[@B18]\]. The hospital also provided information on specimen source and patient age. For analysis, samples from upper respiratory tract were designated as respiratory origin. Samples from pus/discharge included those from abscesses or wounds.

Antimicrobial susceptibility
----------------------------

Minimum inhibitory concentrations (MIC) of different agents were determined by reference broth microdilution test following the guidelines of Clinical and Laboratory Standards Institute (CLSI) using custom designed Sensititre panels (Trek Diagnostics, West Essex, England) \[[@B19]\] Amikacin, ampicillin/sulbactam, ceftazidime, cefepime, ciprofloxacin, gentamicin, levofloxacin, imipenem, and piperacillin/tazobactam were tested on all isolates from each study year. Polymyxin B and tigecycline were tested on imipenem-resistant isolates in 2002 and 2004 and on all isolates from 2008--2010. Trimethoprim-sulfamethoxazole was tested on all isolates from 2002, 2004 and 2010. Control strains included *Pseudomonas aeruginosa* ATCC 27853, *Escherichia coli* ATCC 25922 and ATCC 35218. Results were interpreted using the CLSI breakpoints except for colistin and tigecycline, for which the EUCAST breakpoints (for Enterobacteriaceae) were used (<http://www.eucast.org/clinical_breakpoints>). Isolates nonsusceptible to all the tested aminoglycosides, fluoroquinolones, β-lactam, β-lactam/β-lactam inhibitors, and carbapenems were defined as extensively drug-resistant (XDR) \[[@B20],[@B21]\].This is a modification of the ECDC definition for XDR, which is defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories \[[@B20]\].

Data and statistical analysis
-----------------------------

For analysis of susceptibility rates in different year and patient groups, we used the Whonet software \[[@B22]\]. Univariate analysis was done using Student's *t* test/Mann--Whitney U test, or Fisher's exact tests as appropriate. Multivariate logistic regression analysis was performed to assess the relationship between predictor variables among patients with resistant ABC and patients with non-resistant ABC. The variables included those identified in the univariate analysis as possibly being associated with resistance rate (*P* \< 0.05). For comparison of resistance between regions and specimen types, these variables were entered in the multivariate analysis in a dummy form (resistance rate in northern Taiwan or that of blood samples as the reference group, respectively). For the trend test calculation, a continuous variable (TSAR period III to VII corresponding to 3 to 7, respectively) was used \[[@B23]\]. All analyses were performed with the Statistical Package for the Social Sciences version 18.0 (SPSS, Chicago, IL, USA). A *P* \< 0.05 was considered to be statistically significant.

Results
=======

Bacterial isolates
------------------

Between 2002 and 2010, a total of 1,681 *Acinetobacter* spp. isolates were collected and ABC comprised 97.6% (1,640 isolates). Non-ABC isolates were excluded from subsequent data analysis. Among the 1640 ABC isolates, the mean age of patients was 66.8 ± 19.8 years. Table [1](#T1){ref-type="table"} lists the source breakdown of the isolates for each round of TSAR. Isolates were mostly recovered from respiratory samples (822 isolates, 50.1%), followed by blood (244, 14.9%), pus/discharge (219, 13.4%) and urine (216, 13.2%). Seven hundred and thirty-five (44.8%) were from medical centers and 600 (36.6%) were from ICU. Isolates from central Taiwan comprised the largest proportion (627, 38.2%) (Table [1](#T1){ref-type="table"}).

###### 

**Source breakdown of*Acinetobacter baumannii*complex from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) by year**

  **Strata**                  **TSAR III (2002)**   **TSAR IV (2004)**   **TSAR V (2006)**   **TSAR VI (2008)**   **TSAR VII (2010)**   **TSAR III-VII Combined**   ***P***^***a***^                                   
  -------------------------- --------------------- -------------------- ------------------- -------------------- --------------------- --------------------------- ------------------ ------ ----- ------ ----- ------ --------
  Hospital type                                                                                                                                                                                                        
   Medical centers (11)               162                  54.4                 124                 47.9                  126                     41.4                    172          41.1   151   41.8   735   44.8   0.002
   Regional hospitals (15)            136                  45.6                 135                 52.1                  178                     58.6                    246          58.9   210   58.2   905   55.2   0.002
  Region                                                                                                                                                                                                               
   North (7)                          90                   30.2                 70                  27.0                  76                      25.0                    118          28.2   118   32.7   472   28.8   0.2354
   Central (8)                        94                   31.5                 91                  35.1                  109                     35.9                    189          45.2   144   39.9   627   38.2   0.0024
   South (8)                          77                   25.8                 57                  22.0                  76                      25.0                     65          15.6   68    18.8   343   20.9   0.0032
   East (3)                           37                   12.4                 41                  15.8                  43                      14.1                     46          11.0   31    8.6    198   12.1   0.0194
  Patient location                                                                                                                                                                                                     
   ICU                                100                  33.6                 105                 40.5                  103                     33.9                    157          37.6   135   37.4   600   36.6   0.3848
   Non-ICU                            174                  58.4                 138                 53.3                  165                     54.3                    227          54.3   201   55.7   905   55.2   0.7578
   OPD/ER                             24                   8.1                  16                  6.2                   36                      11.8                     34          8.1    25    6.9    135   8.2    0.1104
  Specimen type                                                                                                                                                                                                        
   Respiratory                        157                  52.7                 136                 52.5                  137                     45.1                    208          49.8   184   51.0   822   50.1   0.3294
   Blood                              33                   11.1                 28                  10.8                  34                      11.2                     84          20.1   65    18.0   244   14.9   0.0002
   Pus/discharge                      49                   16.4                 40                  15.4                  56                      18.4                     40          9.6    34    9.4    219   13.4   0.0005
   Urine                              34                   11.4                 30                  11.6                  50                      16.4                     57          13.6   45    12.5   216   13.2   0.332
   Others                             25                   8.4                  25                  9.7                   27                       8.9                     29          6.9    33    9.1    139   8.5    0.7321
  Total                               298                  259                  304                 418                   361                     1640                                                                 

^a^The differences of hospital types, regions, patient locations, and specimen types among TSAR III to VII were compared using Pearson\'s chi-squared test.

Changes in non-susceptibility to different antimicrobial agents over the years
------------------------------------------------------------------------------

Rates of non-susceptibility to different antimicrobial agents between 2002 and 2010 are shown in Table [2](#T2){ref-type="table"}. The secular trend of non-susceptibility to amikacin, ceftazidime, levofloxacin, and imipenem over the 10 years is also shown in Figure [1](#F1){ref-type="fig"} to highlight the sharp increase of carbapenem (imipenem) non-susceptibility from 3.4% in 2002 to 58.7% in 2010 (*P* \< 0.001; odds ratio \[OR\], 2.138; 95% confidence interval \[CI\], 1.947 to 2.347). The increased carbapenem-resistance was observed in isolates from elderly as well as non-elderly patients, and in those from different specimen types, ICU and non-ICU patients, and throughout different regions of Taiwan (Figure [2](#F2){ref-type="fig"}).

###### 

**Secular trend of antimicrobial non-susceptibility in*Acinetobacter baumannii*complex from the 2002 to 2010 Taiwan Surveillance of Antimicrobial Resistance (TSAR) program**

  **Antimicrobial agents**^**a**^   **Resistance rate (%) by year**   **2002 to 2006**^**b**^   **2006 to 2010**                                                                   
  --------------------------------- --------------------------------- ------------------------- ------------------ ------ ------ --------- ------- ------------- --------- ------- -------------
  Amikacin                          63.1                              68                        70.7               66.5   64.3   0.046     1.19    1.003-1.411   0.081     0.865   0.735-1.018
  Amp/Sulb                          57.4                              64.1                      57.6               61.5   59.6   0.971     1.003   0.852-1.180   0.637     1.038   0.889-1.212
  Cefepime                          64.1                              70.7                      74                 71.3   60.9   0.008     1.265   1.062-1.507   \<0.001   0.731   0.619-0.864
  Ceftazidime                       68.1                              73.4                      76.6               74.6   70.4   0.019     1.241   1.036-1.486   0.063     0.848   0.712-1.009
  Ciprofloxacin                     68.8                              75.3                      76                 75.4   75.3   0.047     1.202   1.002-1.441   0.853     0.983   0.824-1.174
  Gentamicin                        73.5                              78.8                      76.6               70.3   72.9   0.367     1.09    0.904-1.315   0.311     0.915   0.770-1.087
  Imipenem                          3.4                               18.1                      31.6               51.4   58.7   \<0.001   3.043   2.348-3.944   \<0.001   1.732   1.478-2.029
  Levofloxacin                      66.1                              72.6                      74.3               73.9   71.2   0.027     1.222   1.023-1.458   0.349     0.921   0.775-1.094
  Pip/Tazo                          62.8                              76.8                      75.3               74.6   68.4   0.001     1.363   1.139-1.631   0.041     0.835   0.703-0.992
  TMP/SMX                           73.8                              75.7                      NT^c^              NT     71.5   ND^d^                           ND                 

^a^Amp/Sulb, Ampicillin/sulbactam; Pip/Tazo, Piperacillin/tazobactam; TMP/SMX, trimethoprim/sulfamethoxazole.

^b^OR, odds ratio; CI, confidence interval.

^c^NT, not tested.

^d^ND, not done.

![**Rapid increase of imipenem-resistance in*Acinetobacter baumannii*complex (OR 2.277; 95% CI, 2.054-2.523;*P* \< 0.001) in Taiwan based on the Taiwan Surveillance of Antimicrobial Resistance (TSAR) data.** The secular trends of resistance to 4 other agents are shown for comparison.](1471-2334-12-200-1){#F1}

![**Secular trend of imipenem-resistance rate in*Acinetobacter baumannii*complex recovered from 2002 to 2010 in Taiwan.** Differences in resistance rates were stratified by (**a**) patient age, (**b**) sample origins, (**c**) healthcare settings, and (**d**) geographic regions, based on the Taiwan Surveillance of Antimicrobial Resistance (TSAR) data.](1471-2334-12-200-2){#F2}

The rates of non-susceptibility to other antimicrobial agents remained high (\>55%) over the years although fluctuations were observed before and after TSAR V (2006) on some agents (Table [2](#T2){ref-type="table"} & Figure [1](#F1){ref-type="fig"}); non-susceptibility to amikacin, cefepime, ceftazidime, levofloxacin, and piperacillin/tazobactam increased significantly before 2006 (TSAR V), then stayed at a plateau and even declined thereafter (Table [2](#T2){ref-type="table"}). In contrast, the rates of non-susceptibility to ampicillin/sulbactam (range 56.1% - 64.1%) fluctuated over 10 years without significant change (*P* = 0.775; OR, 1.010; 95% CI, 0.942 to 1.084), while that of gentamicin decreased slightly since 2004 (*P* = 0.034; OR, 0.883; 95% CI, 0.787 to 0.991). The overall rate of susceptibility to tigecycline (MIC \< = 2 mg/L) and polymyxin B was 97.7% and 99.8%, respectively in 1,160 tested isolates and 98.1% and 100%, respectively in IRABC.

Factors associated with emergence of imipenem-resistant *A. baumannii* complex (IRABC)
--------------------------------------------------------------------------------------

Table [3](#T3){ref-type="table"} presents the factors associated with the emergence of IRABC. Isolates from elderly patients (\> 65 years old), respiratory tract origin, ICU settings, or central Taiwan were significantly associated with imipenem resistance whereas rates of imipenem-resistance were lower in isolates from blood or pus/discharge, medical centers, southern or northern Taiwan (Figure [2](#F2){ref-type="fig"}). Multivariate analysis revealed recovery from elderly patients, origins other than blood, ICU settings, geographic region, and latter collection year remained independent factors (Table [3](#T3){ref-type="table"}).

###### 

**Factors associated with imipenem-resistant*Acinetobacter baumannii*complex (IRABC) in Taiwan**

  **Characteristic**     **Non-IRABC**   **IRABC**     ***P***^**a**^   **OR**^**b**^   **95% CI**^**b**^   ***P***^**b**^
  ---------------------- --------------- ------------- ---------------- --------------- ------------------- ----------------
  Number                 1060            580                                                                 
   Mean age ± SD^c^      65.0 ± 20.2     70.0 ± 18.8   \<0.001                                               
   Age 65 and older^c^   629 (61.1)      401 (71.9)    \<0.001          1.464           1.122-1.912         0.005
  Specimen types                                                                                            
   Respiratory tracts    481 (45.4)      341 (58.8)    \<0.001          2.597           1.888-3.570         \<0.001
   Blood                 192 (18.1)      52 (9.0)      \<0.001                                              Reference
   Pus/discharge         160 (15.1)      59 (10.2)     0.005            1.934           1.240-3.018         0.004
   Urine                 140 (13.2)      76 (13.1)     \>0.99           2.138           1.401-3.263         \<0.001
  Healthcare settings                                                                                       
   Medical centers       507 (47.8)      228 (39.3)    0.001            0.814           0.631-1.049         0.112
   ICU Settings          328 (30.9)      272 (46.9)    \<0.001          1.919           1.482-2.486         \<0.001
  Geographic regions                                                                                        
   Northern              336 (31.7)      136 (23.4)    \<0.001                                              Reference
   Central               341 (32.2)      286 (49.3)    \<0.001          2.43            1.791-3.296         \<0.001
   Southern              258 (24.3)      85 (14.7)     \<0.001          1.178           0.812-1.710         0.388
   Eastern               125 (11.8)      73 (12.6)     0.635            2.24            1.489-3.370         \<0.001
  TSAR period^d^                                                        2.277           2.054-2.523         \<0.001

^a^*P* value by chi-square test.

^b^*P* value by multivariate analysis; OR, odds ratio; CI, confidence interval.

^c^The patient ages for 50 patients were unknown.

^d^Taiwan Surveillance of Antimicrobial Resistance (TSAR) III (2002) to VII (2010).

Emergence of extensively drug-resistant *A. baumannii* complex (XDRABC)
-----------------------------------------------------------------------

The prevalence of XDRABC increased significantly from 1.3% in 2002 to 41.0% in 2010, respectively (*P* \<0.001; OR, 1.970; 95% CI, 1.773-2.189), with an overall prevalence of 26.1% (428 isolates) over the 10 years. The increased XDRABC also occurred in isolates from elderly and non-elderly patients both, and in those from different specimen types, ICU as well as non-ICU patients, while central region saw a sharp increase of XDRABC in 2008--2010 (Figure [3](#F3){ref-type="fig"}). Ten (2.3%) of the XDRABC had tigecycline \> 2 mg/L and all were susceptible to polymyxin B. Trimethoprim-sulfamethoxazole was tested on 187 XDRABC isolates and all but 4 were resistant.

![**Secular trend of extensively drug-resistance rate in*Acinetobacter baumannii*complex recovered from 2002 to 2010 in Taiwan.** Differences in resistance rates were stratified by (**a**) patient age (**b**) sample origins (**c**) healthcare settings (**d**) geographic regions based on the Taiwan Surveillance of Antimicrobial Resistance (TSAR) data.](1471-2334-12-200-3){#F3}

Factors associated with emergence of XDRABC
-------------------------------------------

Factors associated with XDRABC strains included recovery from elderly patients (\> 65 years old), respiratory tract origin, ICU settings, or central Taiwan (Table [4](#T4){ref-type="table"}). The extensively drug-resistant rates over 10 years stratified by these independent factors are shown in Figure [3](#F3){ref-type="fig"}. Isolates from blood or pus/discharge, medical center, southern or northern Taiwan were less likely to be XDR. The independent factors associated with XDRABC included recovery from elderly patients, origins other than blood, ICU settings, geographic region, and latter collection year (Table [4](#T4){ref-type="table"}).

###### 

**Factors associated with extensively drug-resistant*Acinetobacter baumannii*complex (XDRABC) in Taiwan**

  **Characteristic**     **Non-XDRABC**   **XDRABC**    ***P***^**a**^   **OR**^**b**^   **95% CI**^**b**^   ***P***^**b**^
  ---------------------- ---------------- ------------- ---------------- --------------- ------------------- ----------------
  Number                 1212             428                                                                 
   Mean age ± SD^c^      65.4 ± 20.2      70.6 ± 18.1   \<0.001                                               
   Age 65 and older^c^   733 (71.2)       297 (28.8)    \<0.001          1.39            1.052-1.836         0.021
  Specimens                                                                                                  
   Respiratory tracts    571 (47.1)       251 (58.6)    \<0.001          2.102           1.507-2.932         \<0.001
   Blood                 210 (17.3)       34 (7.9)      \<0.001                                              Reference
   Pus/discharge         176 (14.5)       43 (10.0)     0.02             1.598           0.996-2.568         0.052
   Urine                 160 (13.2)       56 (13.1)     \>0.99           1.759           1.130-2.739         0.012
  Healthcare settings                                                                                        
   Medical centers       570 (47.0)       165 (38.6)    0.003            0.804           0.617-1.046         0.104
   ICU settings          404 (33.3)       196 (45.8)    \<0.001          1.468           1.126-1.915         0.005
  Geographic regions                                                                                         
   Northern              365 (30.1)       107 (25.0)    0.047                                                Reference
   Central               404 (33.3)       223 (52.1)    \<0.001          1.965           1.466-2.671         \<0.001
   Southern              290 (23.9)       53 (12.4)     \<0.001          0.814           0.544-1.216         0.314
   Eastern               153 (12.6)       45 (10.5)     0.263            1.303           0.847-2.006         0.229
  TSAR period^d^                                                         1.97            1.773-2.189         \<0.001

^a^*P* value by chi-square test.

^b^*P* value by multivariate analysis; OR, odds ratio; CI, confidence interval.

^c^The patient ages of 50 patients were unknown.

^d^Taiwan Surveillance of Antimicrobial Resistance (TSAR) III (2002) to VII (2010).

Discussion
==========

This nationwide longitudinal study of 1,640 ABC over 10 years revealed the continuous increase of non-susceptibility to imipenem and emergence of XDRABC. For most other antibiotics, resistance rate increased from 2002 to 2006 but ceased to increase or even decreased thereafter. The prevalence of IRABC and XDRABC was independently affected by age of patients, specimen types, healthcare settings, and geographic regions.

Resistance to imipenem, which is often accompanied with resistance to multiple other agents, has increased in all parts of the world, ranging from 14.1% in Europe to 39.4% in Latin America in 2004--2006 \[[@B24]\], and from 34.5% in 2006 to 59.8% in 2009 overall worldwide \[[@B9]\]. Our study revealed the rapid increase in the prevalence of imipenem-resistance over 10 years in Taiwan, from 3.4% in 2002 to 58.7% in 2010. The imipenem-nonsusceptible rate of 62.6% in isolates from Asia-Pacific in 2009 reported by the SENTRY study was comparable to our result \[[@B9]\].

Although XDRABC in Taiwan has been observed in other pilot studies \[[@B10],[@B14]\], this is the first study addressing the emergence of XDRABC in Taiwan over a long period. However, the variety of definition regarding XDR precluded the comparison of our data with previous ones. The definition of XDR in our study was in accordance to that of Tan et al. \[[@B21]\] and approached the consensus of European Centre for Disease Prevention and Control \[[@B20]\] except that not all isolates were tested for trimethoprim-sulfamethoxazole. However, almost all of XDRABC tested showed resistance to it.

Prolonged hospitalization, ICU stay, invasive medical procedures, and prior broad-spectrum antibiotic use, especially carbapenem, third-generation cephalosporins, and fluoroquinolones, have been shown to be risk factors for acquisition of IRABC \[[@B4],[@B7],[@B25]\]. These factors, as well as clonal dissemination \[[@B26],[@B27]\], likely all contributed to the increased prevalence of IRABC and XDRABC in Taiwan over the years. A recent study found carbapenem use in Taiwan hospitals increased by 86% between 2003 and 2008, which was significantly associated with increased healthcare associated IRABC infections \[[@B28]\]. The same study also found that the largest increase in carbapenem use occurred in the central region, the area we found the highest prevalence of IRABC and XDRABC. Strain variability and differences in oxacillinase distribution \[[@B26],[@B27]\] may also account for regional differences and the changes in resistance after 2006, and remain to be investigated.

Based on the independent associated factors we identified, the prevalence of imipenem-resistance and XDRABC varied greatly. To our knowledge, variations in resistance profiles among ABC from different sample origins have rarely been addressed before. Whether the lower resistance of isolates from blood compared to other sample origins resulted from different clonality and/or impaired virulence in the cost of resistance \[[@B29]\] remained to be elucidated. Varied prevalence among different areas and healthcare settings (ICU) in Asia has been observed \[[@B10]\]. The insignificant difference between medical centers and regional hospitals may have resulted from frequent transportation of patients and high density of hospitals in Taiwan. The advanced age may imply the underlying conditions of the patients. Higher prevalence of IRABC and XDRABC in ICU and regional variations within Taiwan likely reflect differences in patient populations and antibiotic use \[[@B28],[@B30]\].

The rate of resistance to polymyxin B in our study was only 0.2%, which is similar to that found in isolates from the Asia-Western Pacific region between 2006 and 2009 \[[@B9]\]. In contrast, one study in Korea reported a resistance rate of 18.1% \[[@B31]\]. As for tigecycline, 0.2% of IRABC isolates had MIC \> 2 mg/L in Asia region \[[@B32]\] whereas our study found it to be 1.9% in Taiwan. Susceptibility to polymyxin remained high even for the XDRABC isolates in our study. However, in a pilot study by Jean et al., \[[@B14]\], the authors reported higher rate of resistance to colistin and tigecycline in Taiwan. The source of isolates differed in the two studies. Ours were from different patient groups of both teaching and regional hospitals while theirs were from ICUs of ten major teaching hospitals. The underlying conditions, disease severity, and amount of colistin and tigecycline used would be different. However, both studies revealed that compared to other antibiotics, tigecycline and polymyxin B (or its less toxic derivatives, colistin) remained an in vitro effective antimicrobial agent for the treatment of IRABC or XDRABC in Taiwan.

Conclusion
==========

This longitudinal multicenter surveillance program revealed significant increase and nationwide emergence of IRABC and XDRABC in Taiwan despite that non-susceptibility to other antibiotics remained stable or declined over the past 6 years. This study also identified factors associated with their resistance to help guide empirical therapy and at-risk groups requiring more intense interventional infection control measures with focused surveillance efforts.
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